

Jalpa A Doshi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1352958/publications.pdf>

Version: 2024-02-01

59
papers

2,570
citations

331670

21
h-index

197818

49
g-index

60
all docs

60
docs citations

60
times ranked

4139
citing authors

#	ARTICLE	IF	CITATIONS
1	DLMM as a lossless one-shot algorithm for collaborative multi-site distributed linear mixed models. <i>Nature Communications</i> , 2022, 13, 1678.	12.8	9
2	dPQL: a lossless distributed algorithm for generalized linear mixed model with application to privacy-preserving hospital profiling. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 1366-1371.	4.4	10
3	Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics. <i>JAMA Health Forum</i> , 2022, 3, e221435.	2.2	4
4	Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population. <i>Movement Disorders</i> , 2021, 36, 133-142.	3.9	23
5	Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic. <i>JAMA Internal Medicine</i> , 2021, 181, 471.	5.1	197
6	Low Sustainment of High-Dose Oral Medication Regimens for Advanced Parkinson's Disease in Medicare Beneficiaries. <i>Journal of Parkinson's Disease</i> , 2021, 11, 675-684.	2.8	4
7	Patient and Hospital Factors Associated With Differences in Mortality Rates Among Black and White US Medicare Beneficiaries Hospitalized With COVID-19 Infection. <i>JAMA Network Open</i> , 2021, 4, e2112842.	5.9	63
8	Novel population-level proxy measures for suboptimal HIV preexposure prophylaxis initiation and persistence in the USA. <i>Aids</i> , 2021, 35, 2375-2381.	2.2	11
9	Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1457-1468.	0.9	8
10	Trends in US Patients Receiving Care for Eating Disorders and Other Common Behavioral Health Conditions Before and During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2134913.	5.9	30
11	Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 507-515.e10.	3.8	13
12	Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?. <i>Population Health Management</i> , 2020, 23, 234-242.	1.7	3
13	Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions. <i>Value in Health</i> , 2020, 23, 209-216.	0.3	5
14	Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis. <i>Value in Health</i> , 2020, 23, 328-334.	0.3	16
15	Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR). <i>Journal of Medical Economics</i> , 2020, 23, 1072-1083.	2.1	8
16	The Changing Characteristics of Technologies Covered by Medicare's New Technology Add-on Payment Program. <i>JAMA Network Open</i> , 2020, 3, e2012569.	5.9	2
17	Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: Associations with claims-based indicators of disease severity. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100046.	0.9	7
18	Early hypoglycaemia and adherence after basal insulin initiation in a nationally representative sample of Medicare beneficiaries with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2486-2495.	4.4	10

#	ARTICLE	IF	CITATIONS
19	Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2019, 2, e195806.	5.9	14
20	The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 737-743.	2.2	2
21	Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]. <i>Value in Health</i> , 2018, 21, 131-139.	0.3	321
22	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. <i>Value in Health</i> , 2018, 21, 161-165.	0.3	113
23	Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e003939.	2.2	31
24	Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. <i>Haematologica</i> , 2018, 103, e462-e465.	3.5	15
25	Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study. <i>Health Services Research</i> , 2018, 53, 2735-2757.	2.0	22
26	Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 75-86.	2.8	18
27	Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents. <i>Journal of Clinical Oncology</i> , 2018, 36, 476-482.	1.6	104
28	A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 283-292.	1.4	1
29	Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia. <i>Journal of Medical Economics</i> , 2017, 20, 1252-1260.	2.1	12
30	Prevalence and Correlates of Anti-Parkinson Drug Use in a Nationally Representative Sample. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 335-341.	1.5	22
31	Synchronized prescription refills and medication adherence: a retrospective claims analysis. <i>American Journal of Managed Care</i> , 2017, 23, 98-104.	1.1	8
32	Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon". <i>American Journal of Managed Care</i> , 2017, 23, S39-S45.	1.1	9
33	Impact of Medicare Advantage Prescription Drug Plan Star Ratings on Enrollment before and after Implementation of Quality-Related Bonus Payments in 2012. <i>PLoS ONE</i> , 2016, 11, e0154357.	2.5	10
34	Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	3
35	Disparities in Absolute Denial of Modern Hepatitis C Therapy—by Type of Insurance. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1035-1043.	4.4	111
36	Two Randomized Controlled Pilot Trials of Social Forces to Improve Statin Adherence among Patients with Diabetes. <i>Journal of General Internal Medicine</i> , 2016, 31, 402-410.	2.6	22

#	ARTICLE	IF	CITATIONS
37	A Synchronized Prescription Refill Program Improved Medication Adherence. <i>Health Affairs</i> , 2016, 35, 1504-1512.	5.2	44
38	Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. <i>Cancer Medicine</i> , 2016, 5, 169-181.	2.8	82
39	A randomized trial of lottery-based incentives and reminders to improve warfarin adherence: the Warfarin Incentives (WIN2) Trial. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1219-1227.	1.9	22
40	Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1624-1630.	3.4	13
41	Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1057-1065.e4.	1.2	102
42	Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions. <i>American Journal of Managed Care</i> , 2016, 22, 188-97.	1.1	24
43	High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. <i>American Journal of Managed Care</i> , 2016, 22, s78-86.	1.1	25
44	Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. <i>Lancet Haematology</i> , 2015, 2, e408-e416.	4.6	158
45	Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 442-446.	1.4	34
46	Comparative Effectiveness And Cost-Effectiveness Analyses Frequently Agree On Value. <i>Health Affairs</i> , 2015, 34, 805-811.	5.2	17
47	Utility of interim and end-of-treatment [¹⁸ F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2579-2584.	1.3	16
48	Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2955-2963.	0.7	107
49	Assessing financial toxicity in insured patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 6600-6600.	1.6	0
50	Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 6526-6526.	1.6	1
51	Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2014, 32, 8549-8549.	1.6	0
52	Effect of the Medicare Part D Coverage Gap on Medication Use Among Patients With Hypertension and Hyperlipidemia. <i>Annals of Internal Medicine</i> , 2012, 156, 776.	3.9	57
53	Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2012, 51, 990-1002.e2.	0.5	329
54	Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review. <i>Clinical Therapeutics</i> , 2011, 33, 901-913.	2.5	101

#	ARTICLE	IF	CITATIONS
55	Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis. <i>Value in Health</i> , 2010, 13, 805-812.	0.3	74
56	Impact of the medicare modernization act of 2003 on utilization and spending for medicare part Bâ€covered biologics in rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2010, 62, 354-361.	3.4	18
57	Drug benefit generosity and essential medication use among Medicare-eligible retirees. <i>American Journal of Managed Care</i> , 2007, 13, 425-31.	1.1	6
58	Analyses of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled Trials. <i>Value in Health</i> , 2006, 9, 334-340.	0.3	57
59	The Impact Of Drug Coverage On COX-2 Inhibitor Use In Medicare. <i>Health Affairs</i> , 2004, 23, W4-94-W4-105.	5.2	17